比较非布司他片与别嘌呤醇片治疗高尿酸血症伴痛风的临床研究

发布时间：2018-10-11 17:30

【摘要】：目的观察不同剂量非布司他与别嘌呤醇治疗高尿酸血症伴痛风的临床疗效及安全性。方法将90例高尿酸血症伴痛风患者随机分为试验A组、试验B组和对照组,每组30例。对照组患者予以口服别嘌呤醇片300 mg tid;试验A组患者予以口服非布司他片35 mg qd,试验B组患者予以口服非布司他片70mg qd,3组患者均治疗24周。比较3组患者的临床疗效和药物不良反应发生率,以及治疗前、治疗12周及24周时患者的血清可溶性细胞黏附因子-1(s ICAM-1)水平和尿酸水平。结果治疗后,试验A组、试验B组和对照组的总有效率分别为56.67%(17例/30例),66.67%(20例/30例)和46.67%(14例/30例),差异均有统计学意义(均P0.05)。治疗后12周,试验A组、试验B组和对照组的血清s ICAM-1分别为(445.76±135.85),(421.28±122.25)和(493.39±121.27)ng·mL~(-1);治疗后24周,试验A组、试验B组和对照组的血清s ICAM-1分别为(387.71±126.75),(360.85±125.50)和(441.45±122.48)ng·mL~(-1),差异均有统计学意义(均P0.05);分别与治疗前比较,差异均有统计学意义(均P0.05)。治疗后12周,试验A组、试验B组和对照组的尿酸分别为(445.57±135.50),(460.60±140.45)和(515.20±142.15)ng·mL~(-1);治疗后24周,试验A组、试验B组和对照组的尿酸分别为(425.10±126.28),(410.10±130.38)和(478.80±164.72)ng·mL~(-1),差异均有统计学意义(均P0.05);分别与治疗前比较,差异均有统计学意义(均P0.05)。试验组和对照组在治疗过程中均未发生明显药物不良反应。结论非布司他可降低高尿酸血症伴痛风患者的血清s ICAM-1水平和尿酸水平,临床疗效优于别嘌呤醇。
[Abstract]:Objective to observe the efficacy and safety of different doses of nonbuflast and allopurinol in the treatment of hyperuricemia with gout. Methods 90 patients with hyperuricemia and gout were randomly divided into three groups: group A, group B and control group. Patients in the control group were treated with oral allopurinol 300 mg tid; test group A and group B were treated with non-busultam tablets for 35 mg qd,. The patients in the 70mg qd,3 group were treated for 24 weeks. The clinical efficacy and incidence of adverse drug reactions, serum soluble cell adhesion factor-1 (s ICAM-1) and uric acid levels were compared between the three groups before and after 12 and 24 weeks of treatment. Results after treatment, the total effective rates of group A, group B and control group were 56.67% (17 / 30), 66.67% (20 / 30) and 46.67% (14 / 30), respectively (P0.05). At 12 weeks after treatment, the serum s ICAM-1 levels in group A, group B and control group were (445.76 卤135.85), () 421.28 卤122.25 and (493.39 卤121.27) ng mL~ (-1), respectively, and 24 weeks after treatment, those in group A were (445.76 卤135.85), (卤122.25) and (493.39 卤121.27) ng mL~ (-1), respectively. The serum s ICAM-1 of group B and control group were (387.71 卤126.75), (360.85 卤125.50) and (441.45 卤122.48) ng mL~ (P 0.05), respectively. At 12 weeks after treatment, uric acid levels in group A, group B and control group were (445.57 卤135.50), (460.60 卤140.45) and (515.20 卤142.15) ng mL~ (-1), respectively, 24 weeks after treatment, uric acid in group A, group B and control group were (425.10 卤126.28), (410.10 卤130.38) and (478.80 卤164.72) ng mL~ (-1), respectively. The difference was statistically significant (P0.05). There were no significant adverse drug reactions in the treatment process in both the experimental group and the control group. Conclusion the serum s ICAM-1 level and uric acid level in patients with hyperuricemia and gout can be decreased by using fentinast, and the clinical efficacy is better than that of allopurinol.
【作者单位】：福建莆田学院附属医院药剂科;福建省疾病预防控制中心;
【基金】：福建省卫生计生委青年科研课题基金资助项目(2015-2-26)
【分类号】：R589.7

【相似文献】